CA-DRISHTI-TECHNOLOGIES
24.3.2022 11:02:14 CET | Business Wire | Press release
Drishti Technologies, Inc. (Drishti), whose AI-powered manufacturing technology uses video analytics, data and insights to bring significant benefits to manufacturers and their employees, and HELLA (FRA:HLE) a tier-one automotive supplier, today announced the latest in a joint effort to further increase operational efficiency with a second successful combined project in Dhankot, India. HELLA is an internationally positioned automotive supplier globally recognized for its lean practices and is committed to investing in the latest technologies to drive human productivity and improve manufacturing outcomes.
With Drishti cameras and streaming video analysis enabled on one of HELLA’s sensor product lines, the HELLA team made a series of previously concealed discoveries. First, the massive volume of cycle time data available from Drishti quickly revealed slowdowns in stations that were not originally the focus of improvement efforts. Second, by watching video footage from the identified station, the team understood that the physical station configuration was slowing down the line associates.
In fact, the station setup was causing ergonomic concerns. Because the line associate was reaching with his right arm across to the left side of the station, each cycle required a twisting motion that led to fatigue.
“Because our focus had been on the station we thought was the bottleneck, we had overlooked this potential for slowdowns and fatigue,” said Ram Singh Khangarote, operational excellence and operation product manager, HELLA Dhankot. “Within a few minutes of viewing the video footage from Drishti, our team had ideas to reconfigure the station to make it more comfortable for the line associates, and shortening every cycle time. And most importantly, our line associates are healthier, happier and more productive.”
Finally, with Drishti, because the team in Dhankot learned the true cause of line slowdowns, they were able to improve line balancing. The Drishti investment paid for itself in less than six months.
“This is the second instance of finding significant improvement opportunities using Drishti. In 2020, we reduced cycle times in our Guanajuato, Mexico plant . Now we’re seeing value in Dhankot, as well,” said Huri Mendoza, head of operational excellence, HELLA. “Drishti’s technology perfectly complements our goal of achieving operational excellence by augmenting our extremely capable workforce and empowering them with the tools they need to perform their jobs even better.”
The Dhankot plant deployment is one of several ongoing collaborations between HELLA and Drishti. Drishti streams video at every station on a line, then uses proprietary AI networks to translate video streams into data, a technique called action recognition. The line-level data on cycles and actions helps manufacturers improve productivity and quality while improving standardized work adherence.
“Drishti’s action recognition technology provides manufacturers with a clear competitive edge, as they can see improvement opportunities on assembly lines that are otherwise hidden,” said Gary Jackson, CEO, Drishti. “HELLA’s success with Drishti is in line with what we’re seeing across the automotive industry, as well as in other verticals like electronics and medical devices. The future of automated video analysis, which creates insights on people at work, runs through Drishti.”
About Drishti
Drishti’s AI-powered video analytics technology augments human workers and provides visibility and insights that transform the pace and impact of manual assembly line improvement. Manufacturers use Drishti to anchor true digital transformation, driving sweeping improvements in quality costs, efficiency gains & time-to-proficiency for line associate training. And line associates rely on Drishti to be more consistent and efficient, becoming even more valuable on the factory floor. Drishti has been recognized as a World Economic Forum Technology Pioneer and a Forbes AI 50 company, among others. For more information, visit drishti.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
